Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services
The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management.
Health care services provider Encompass Health (NYSEEHC)
will be announcing earnings results tomorrow after the bell. Here’s what investors should know.
Healthcare diagnostics company Quest Diagnostics (NYSEDGX) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 14.6% year on year to $2.62 billion. Its non-GAAP profit of $2.23 per share was 2.1% above analysts’ consensus estimates.
Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.
The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and earnings hits are “unrecoverable.”
